ClinicalTrials.gg
CompletedNCT01435759Updated Jun 9, 2021Results posted

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Phase 2 interventional study of Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg and Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg in Major Depressive Disorder, sponsored by Shire. Completed at 82 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2011, registered Sep 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,197
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.

Enrollment
3rd of 24
1,197 · median 580
Started
2011
with 5 others
Phase 2
4 of 26
none open now
Registered
15th of 26
by date

Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 4 in phase 2, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Major by Takeda, or all of them as a file.
02

Study summary

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. The purpose of this study is to help answer the following questions:

  • How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
  • Can SPD489 help patients with depression who are also taking an antidepressant?
  • How much SPD489 should be given to patients with depression who are also taking an antidepressant?
  • How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is able to provide written, personally signed and dated to participate in the study before completing any study-related procedures.
  2. Subject is between 18-65 years of age.
  3. Subject has a primary diagnosis of non-psychotic MDD.
  4. Subject has a MADRS total score 24
  5. Subject is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol.
  6. Subject, who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test and agrees to comply with any applicable requirements.
  7. Subject is able to swallow a capsule.

Exclusion criteria

Exclusion Criteria

  1. Subject whose current episode of MDD has not responded to an adequate treatment regimen.
  2. Subject who has a lifetime history of treatment resistant depression, defined as having not responded to adequate treatment with 2 or more treatment regimens.
  3. Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms.
  4. Subject has been hospitalized (within the last 12 months) for their current MDD episode.
  5. Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
  6. Subject has a first degree relative that has been diagnosed with bipolar I disorder.
  7. Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder.
  8. Subject is considered a suicide risk, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
  9. Subject has a concurrent chronic or acute illness or unstable medical condition.
  10. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
  11. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medication.
  12. Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
  13. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  14. Subject has glaucoma.
  15. Subject has any or clinical laboratory abnormalities at the Screening Visit.
  16. Subject has a history of moderate to severe hypertension.
  17. Current use of any other medication (including over-the-counter [OTC], herbal or homeopathic preparations) that has central nervous system effects.
  18. Subject has the potential to need to initiate or modify frequency of psychotherapy or to continue or initiate other treatments for depression, outside of those allowed in this protocol.
  19. Subject has had electroconvulsive therapy for the current depressive episode 3 months prior to the Lead-in Baseline Visit.
  20. The subject has a known or suspected intolerance or to the product.
  21. The subject has a known or suspected intolerance or hypersensitivity to any of the possible antidepressant treatments (escitalopram oxalate or venlafaxine HCL extended release.
  22. Subject has a positive urine drug result.
  23. Subject has a of \<18.5 or >40.
  24. Subject is female and is pregnant or nursing.
  25. Subject has participated in another clinical study involving SPD489/NRP104 or has previously used commercial lisdexamfetamine dimesylate.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,197 participants (actual)

Study arms

  • Experimental
    Antidepressant + SPD489 10 mg

    Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

  • Experimental
    Antidepressant + SPD489 30 mg

    Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg

  • Experimental
    Antidepressant + SPD489 50 mg

    Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg

  • Experimental
    Antidepressant + SPD489 70 mg

    Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg

  • Placebo comparator
    Antidepressant + Placebo

    Drug: Antidepressant + Placebo

Interventions

  • DrugAntidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Drug page: Lisdexamfetamine

    Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks

    Also known as: Vyvanse

  • DrugAntidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg

    Drug page: Lisdexamfetamine

    Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks

    Also known as: Vyvanse

  • DrugAntidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg

    Drug page: Lisdexamfetamine

    Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks

    Also known as: Vyvanse

  • DrugAntidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg

    Drug page: Lisdexamfetamine

    Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks

    Also known as: Vyvanse

  • DrugAntidepressant + Placebo

    oral, once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.

    Time frame: Augmentation Baseline (Week 8) to Week 16

Secondary outcomes

  1. Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16

    Time frame: From Augmentation Baseline (Week 8) to Week 16

  2. Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16

    Time frame: From Augmentation Baseline (Week 8) to Week 16

  3. Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16

    Time frame: From Augmentation Baseline (Week 8) to Week 16

07

Results

Posted Feb 19, 2015

Participant flow

Antidepressant Lead-in Phase
Participant flow — Antidepressant Lead-in Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Started119700000
Completed85500000
Not completed34200000
Withdrew: Adverse event4000000
Withdrew: Protocol violation1600000
Withdrew: Withdrawal by subject7400000
Withdrew: Lost to follow-up8300000
Withdrew: Met bp or pulse withdrawal criteria1000000
Withdrew: Other11900000
Double-blind Phase
Participant flow — Double-blind Phase
MilestoneAntidepressant + Single-blind PlaceboAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Started4637878787880
Completed3977171696971
Not completed6677999
Withdrew: Adverse event701113
Withdrew: Protocol violation201201
Withdrew: Withdrawal by subject1743422
Withdrew: Lost to follow-up3112033
Withdrew: Met bp or pulse withdrawal criteria100030
Withdrew: Other820200

Outcome measures

SecondaryChange in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
Time frame:
From Augmentation Baseline (Week 8) to Week 16
Reported as:
Mean · mmHg
Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
mmHgAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16-0.2 ± 9.550.2 ± 8.580.5 ± 9.173.5 ± 7.822.6 ± 10.55
Statistical analysis
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.004 · Least squares mean: 3.16The t-statistic used for this analysis, 3.14, was based on MCP-Mod Analysis for the candidate model EMax.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.032 · Least squares means: 2.50The t-statistic used for this analysis, 2.48, was based on MCP-Mod Analysis for the candidate model Exponential.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.003 · Least squares mean: 3.28The t-statistic used for this analysis, 3.26 was based on MCP-Mod Analysis for the candidate model Linear.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis Method · p = 0.010 · Least squares means: 2.91The t-statistic used for this analysis, 2.88, was based on MCP-Mod Analysis for the candidate model Logistic1.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.005 · Least squares means: 3.15The t-statistic used for this analysis, 3.12, was based on MCP-Mod Analysis for the candidate model Logistic2.
SecondaryChange in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
Time frame:
From Augmentation Baseline (Week 8) to Week 16
Reported as:
Mean · mmHg
Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16
mmHgAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16-0.1 ± 6.69-0.9 ± 6.64-0.1 ± 7.392.8 ± 6.581.9 ± 7.45
Statistical analysis
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg · MCP-Mod Analysis · p = 0.011 · Least squares means: 2.16The t-statistic used for this analysis, 2.86 was based on MCP-Mod Analysis for the candidate model Emax.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.023 · Least squares means: 1.95The t-statistic used for this analysis, 2.59, was based on MCP-Mod Analysis for the candidate model Exponential.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · Least Squares Means · p = 0.003 · Mcp-mod analysis: 2.47The t-statistic used for this analysis, 3.28, was based on MCP-Mod Analysis for the candidate model Linear.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.009 · Least squares means: 2.22The t-statistic used for this analysis, 2.93, was based on MCP-Mod Analysis for the candidate model Logistic1.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.005 · Least squares means: 2.37The t-statistic used for this analysis, 3.13, was based on MCP-Mod Analysis for the candidate model Logistic2.
SecondaryChange in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16
Time frame:
From Augmentation Baseline (Week 8) to Week 16
Reported as:
Mean · bpm
Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16
bpmAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16-0.8 ± 9.950.8 ± 7.325.3 ± 8.084.0 ± 9.806.0 ± 11.25
Statistical analysis
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = <0.001 · Least squares means: 4.45The t-statistic used for this analysis, 4.24, was based on MCP-Mod Analysis for the candidate model Emax
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.002 · Least squares means: 3.52The t-statistic used for this analysis, 3.36, was based on MCP-Mod Analysis for the candidate model Expontential.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = <0.001 · Least squares means: 4.30The t-statistic used for this analysis, 4.10, was based on MCP-Mod Analysis for the candidate model Linear.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = <0.001 · Least squares means: 4.63The t-statistic used for this analysis, 4.39, was based on MCP-Mod Analysis for the candidate model Logistic1.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = <0.001 · Least squares means: 4.63The t-statistic used for this analysis, 4.39 was based on MCP-Mod Analysis for the candidate model Logistic2.
PrimaryChange in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.

Time frame:
Augmentation Baseline (Week 8) to Week 16
Reported as:
Least squares mean · units on a scale
Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)
units on a scaleAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)-5.4 (-7.2 to -3.5)-6.7 (-8.6 to -4.9)-5.3 (-7.1 to -3.4)-6.1 (-8.1 to -4.1)-6.3 (-8.2 to -4.4)
Statistical analysis
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis Method · p = 1.000 (Any p-value \<=0.10 indicates successful establishment of dose-response relationship.) · Least squares means: -.11The t-statistic used for this analysis, 0.10, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Betamod.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.942 (Any p-value \<=0.10 indicates successful establishment of dose-response relationship.) · Least squares means: 0.43The t-statistic used for this analysis, 0.41, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Emax.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.995 (Any p-value \<=0.10 indicates successful establishment of dose-response relationship.) · Least squares means: 0.21The t-statistic used for this analysis, 0.20, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Linear.
  • Antidepressant + Double-blind Placebo vs Antidepressant + Double-blind SPD489 10mg vs Antidepressant + Double-blind SPD489 30mg vs Antidepressant + Double-blind SPD489 50mg vs Antidepressant + Double-blind SPD489 70mg · MCP-Mod Analysis · p = 0.978 (Any p-value \<=0.10 indicates successful establishment of dose-response relationship.) · Least squares means: -.32The t-statistic used for this analysis, 0.30, was based on MCP-Mod Analysis from the linear contrast using optimal coefficients for the pre-specified candidate model Logistic.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Antidepressant + Double-blind Placebo—0/78 (0%)20/78 (25.6%)
Antidepressant + Double-blind SPD489 10mg—0/77 (0%)30/77 (39%)
Antidepressant + Double-blind SPD489 30mg—0/76 (0%)29/76 (38.2%)
Antidepressant + Double-blind SPD489 50mg—0/78 (0%)36/78 (46.2%)
Antidepressant + Double-blind SPD489 70mg—1/80 (1.3%)44/80 (55%)
Most frequent serious events
Most frequent serious events
EventAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
CholecystitisHepatobiliary disorders0/780/770/760/781/80
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAntidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mg
Dry mouthGastrointestinal disorders1/782/772/7610/7810/80
HeadacheNervous system disorders10/787/775/763/788/80
InsomniaPsychiatric disorders2/787/772/768/789/80
NasopharyngitisInfections and infestations0/785/774/762/787/80
NauseaGastrointestinal disorders1/785/776/761/786/80
BruxismPsychiatric disorders1/780/771/764/786/80
Decreased appetiteMetabolism and nutrition disorders1/784/775/765/784/80
Urinary tract infectionInfections and infestations5/781/772/761/782/80
DizzinessNervous system disorders2/782/772/765/781/80
DiarrhoeaGastrointestinal disorders4/782/773/762/785/80

Baseline characteristics

Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 post-augmentation baseline safety assessment (e.g. coming back for any visit, reporting of an adverse event \[AE\] or reporting the absence of AEs). Subjects who received only single-blind placebo were not included in this group.

Age, Continuous
Age, Continuous(Years)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mgTotal
Mean43.7 ± 10.4839.1 ± 11.8343.4 ± 12.0643.8 ± 12.441.5 ± 10.8142.3 ± 11.61
Age, Customized
Age, Customized(Participants)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mgTotal
18-556970626071332
56-65971418957
Sex: Female, Male
Sex: Female, Male(Participants)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mgTotal
Female5353525353264
Male2524242527125
Region of Enrollment
Region of Enrollment(Participants)Antidepressant + Double-blind PlaceboAntidepressant + Double-blind SPD489 10mgAntidepressant + Double-blind SPD489 30mgAntidepressant + Double-blind SPD489 50mgAntidepressant + Double-blind SPD489 70mgTotal
ARGENTINA2353518
AUSTRALIA000235
CHILE36129232
UNITED KINGDOM100001
UNITED STATES7268596470333
08

Study locations

82 sites
  • Arkansas Psychiatric Clinic Clinical Research Trials
    Little Rock, Arkansas 72223, United States
  • South Coast Clinical Trials
    Anaheim, California 92804, United States
  • Catalina Research Institute, LLC
    Chino, California 91710, United States
  • Shanti Clinical Trials
    Colton, California 92324, United States
  • Clinical Innovation, Inc.
    Costa Mesa, California 92626, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • Irvine Center for Clinical Research
    Irvine, California 92618, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Provate Practice of Andrew Leuchter, MD
    Los Angeles, California 90024, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Connecticut Clinical Research
    Cromwell, Connecticut 06416, United States
  • Institute of Living
    Hartford, Connecticut 06106, United States
  • The Hospital of Central Connecticut, Psychiatry & Behavioral Health Research
    New Britain, Connecticut 06050, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Private Practice - Amit Vijapura MD
    Jacksonville, Florida 32256, United States
  • Psychiatric Associates
    Lake City, Florida 32025, United States
  • Comprehensive Neuroscience, Inc.
    Miramar, Florida 33027, United States
  • Fideltiy Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Ali A. Kashfi, MD, PA
    Orlando, Florida 32839, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Kolin Research Group
    Winter Park, Florida 32789, United States
  • Institute for Behavioral Medicine, LLC
    Smyrna, Georgia 30080, United States
  • Treatment Research Center, Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Alexian Brothers Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • Psychiatric Medicine Associates, LLC
    Skokie, Illinois 60076, United States
  • Sleep and Behavior Medicine Institute
    Vernon Hills, Illinois 60061, United States
  • Clinical Trials Technology, Inc.
    Prairie Village, Kansas 66206, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • Psyichatric Care and Research Center
    O'Fallon, Missouri 63368, United States
  • Mid-America Clinical Research, LLC
    Saint Louis, Missouri 63109, United States
  • Premier Psychiatric Research Institute, LLC.
    Lincoln, Nebraska 68526, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • CRI Worldwide LLC
    Willingboro, New Jersey 08046, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Clinlabs, Inc.
    New York, New York 10010, United States
  • Mount Sinai School of Medicine
    New York, New York 11029, United States
  • Private Practice - Daniel I. Rifkin MD PC
    West Seneca, New York 14224, United States
  • Clinical Trials of America, Inc.
    Hickory, North Carolina 28601, United States
  • North Coast Clinical Trials, Inc.
    Beachwood, Ohio 44122, United States
  • Ohio State University, Dept. of Psychiatry
    Columbus, Ohio 43210, United States
  • Neurology & Neuroscience Center of Ohio
    Toledo, Ohio 43623, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University Services
    West Chester, Pennsylvania 19380, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • Bay Area Clinical Services
    Friendswood, Texas 77546, United States
  • Houston Clinical Trials, LLC
    Houston, Texas 77098, United States
  • Wharton Research Center, Inc.
    Wharton, Texas 77488, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Alliance Research Group
    Richmond, Virginia 23230, United States
  • Dean Foundation for Health, Research and Education, Inc.
    Middleton, Wisconsin 53562, United States
  • Independent Psychiatric Consultants, SC, dba, IPC Research
    Waukesha, Wisconsin 53188, United States
  • Instituto Nacional de Psicopatologia
    Buenos Aires, C1405BOA, Argentina
  • Cervino
    Buenos Aires, Argentina
  • Centro Medico de Medicina Familiar Mind Out Research
    Caba, 1417, Argentina
  • BA Psychiatric Research Center
    Caba, C1012AAU, Argentina
  • Instituto Medico SAMIC
    Cordoba, Argentina
  • Peninsula Health Mental Health Services
    Frankston, Victoria 3199, Australia
  • Neurotherapy Victoria
    Malvern, Victoria 3144, Australia
  • The Alfred, Monash Alfred Psychiatry Research Centre
    Melbourne, Victoria 3004, Australia
  • The Melbourne Clinic
    Richmond, Victoria 3121, Australia
  • Lyell McEwin Hospital, Mental Health Clinical Trials Unit
    Elizabeth Vale, 5112, Australia
  • Psocomed Estudios Medicos
    Antofagasta, Il Region 1270244, Chile
  • Especialidades Medicas L y S
    Las Condes, Santiago 7560356, Chile
  • Centro de Estudios y Tratemiento de Enfermedades Psiquiatricas
    Las Condes, Santiago 7580307, Chile
  • Biomedica Research Group
    Providencia, Santiago 7500710, Chile
  • Centro de Estudios Clinicos
    Providencia, Santiago 7510186, Chile
  • Unidad de Salud Mental y Psiquietriea Hospital y CRS El Pino
    San Bernardo, Santiago 8053095, Chile
  • Hospital Barros Luco Trudsau
    San Miguel, Santiago 890085, Chile
  • Hollins Park Hospital
    Winwick, Warrington Cheshire WA2 8WA, United Kingdom
  • Radbourne Unit
    Derby, DE22 3NE, United Kingdom
  • ADHD Mental Health Research Unit
    Horsham, RH12 1RJ, United Kingdom
  • Newcastle University, Wolfson Research Centre
    Newcastle upon Tyne, NE4 5PL, United Kingdom
  • Rushcliffe Mental Health Team
    Nottingham, NG2 7PG, United Kingdom
09

References and documents

Publications

  • Richards C, Iosifescu DV, Mago R, Sarkis E, Reynolds J, Geibel B, Dauphin M. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. J Psychopharmacol. 2017 Sep;31(9):1190-1203. doi: 10.1177/0269881117722998. Epub 2017 Aug 31. PubMed 28857719 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Jan 2014, 31 months.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 31 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
StartActual
May 31, 2011
Primary completionActual
Jan 17, 2014
CompletionActual
Jan 17, 2014
Results first posted
Feb 19, 2015
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01435759
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
May 31, 2011
Primary completion
Jan 17, 2014
Completion
Jan 17, 2014
Results posted
Feb 19, 2015
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion